Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER-2/neu is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy. METHODS. Serum levels of HER-2/new (n = 135) and of EGFR (n = 113) were prospectively determined before the start of chemotherapy, after 2 months of treatment, and when progressive disease was diagnosed. RESULTS. Elevated (>15 ng/mL) serum HER-2/neu before the start of chemotherapy was not associated with response rate, whereas elevated serum HER-2/neu at 2 months was significantly associated with reduced long-term clinical benefit (24 weeks) (P

Original languageEnglish
Pages (from-to)509-517
Number of pages9
JournalCancer
Volume110
Issue number3
DOIs
Publication statusPublished - Aug 1 2007

Fingerprint

Breast Neoplasms
Drug Therapy
Serum
Therapeutics

Keywords

  • EGFR
  • Her-2/neu
  • Metastatic breast cancer
  • Metronomic therapy
  • Serum biomarker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{274b70bebe544d9c8493ad75942398b1,
title = "Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy",
abstract = "BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER-2/neu is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy. METHODS. Serum levels of HER-2/new (n = 135) and of EGFR (n = 113) were prospectively determined before the start of chemotherapy, after 2 months of treatment, and when progressive disease was diagnosed. RESULTS. Elevated (>15 ng/mL) serum HER-2/neu before the start of chemotherapy was not associated with response rate, whereas elevated serum HER-2/neu at 2 months was significantly associated with reduced long-term clinical benefit (24 weeks) (P",
keywords = "EGFR, Her-2/neu, Metastatic breast cancer, Metronomic therapy, Serum biomarker",
author = "Sandri, {Maria Teresa} and Johansson, {Harriet Ann} and Laura Zorzino and Michela Salvatici and Rita Passerini and Patrick Maisonneuve and Andrea Rocca and Giulia Peruzzotti and Marco Colleoni",
year = "2007",
month = "8",
day = "1",
doi = "10.1002/cncr.22825",
language = "English",
volume = "110",
pages = "509--517",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy

AU - Sandri, Maria Teresa

AU - Johansson, Harriet Ann

AU - Zorzino, Laura

AU - Salvatici, Michela

AU - Passerini, Rita

AU - Maisonneuve, Patrick

AU - Rocca, Andrea

AU - Peruzzotti, Giulia

AU - Colleoni, Marco

PY - 2007/8/1

Y1 - 2007/8/1

N2 - BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER-2/neu is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy. METHODS. Serum levels of HER-2/new (n = 135) and of EGFR (n = 113) were prospectively determined before the start of chemotherapy, after 2 months of treatment, and when progressive disease was diagnosed. RESULTS. Elevated (>15 ng/mL) serum HER-2/neu before the start of chemotherapy was not associated with response rate, whereas elevated serum HER-2/neu at 2 months was significantly associated with reduced long-term clinical benefit (24 weeks) (P

AB - BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER-2/neu is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was to evaluate the prognostic and predictive role of serum HER-2/neu and serum EGFR in breast cancer patients treated with low-dose chemotherapy. METHODS. Serum levels of HER-2/new (n = 135) and of EGFR (n = 113) were prospectively determined before the start of chemotherapy, after 2 months of treatment, and when progressive disease was diagnosed. RESULTS. Elevated (>15 ng/mL) serum HER-2/neu before the start of chemotherapy was not associated with response rate, whereas elevated serum HER-2/neu at 2 months was significantly associated with reduced long-term clinical benefit (24 weeks) (P

KW - EGFR

KW - Her-2/neu

KW - Metastatic breast cancer

KW - Metronomic therapy

KW - Serum biomarker

UR - http://www.scopus.com/inward/record.url?scp=34547097500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547097500&partnerID=8YFLogxK

U2 - 10.1002/cncr.22825

DO - 10.1002/cncr.22825

M3 - Article

C2 - 17559147

AN - SCOPUS:34547097500

VL - 110

SP - 509

EP - 517

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -